Scientists have established the effectiveness of vaccines they developed to prevent the disfiguring skin disease leishmaniasis in animal studies, and Phase 1 human trial planning is in motion for the most promising candidate.
Tevogen to go public in $1.2bn SPAC deal – Pharmaceutical Technology
The combined company will trade under the name Tevogen Holdings, the transaction expected to be completed in the fourth quarter of 2023. Image credit: Shutterstock/kan_khampanya
June 29, 2023